{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:46:16Z","timestamp":1789526776333,"version":"build-2803163510"},"reference-count":62,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1804,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2010.02498.x","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T17:54:43Z","timestamp":1285264483000},"page":"35-43","source":"Crossref","is-referenced-by-count":50,"special_numbering":"supplement s167","title":["Liraglutide in clinical practice: dosing, safety and efficacy"],"prefix":"10.1155","volume":"64","author":[{"given":"G. E.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D.","family":"Pollom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,23]]},"reference":[{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI29189","article-title":"Insulin resistance and pancreatic beta cell failure","volume":"116","author":"Kasuga","year":"2006","journal-title":"J Clin Invest"},{"issue":"Suppl.","key":"10.1111\/j.1742-1241.2010.02498.x-BIB2|cit2","first-page":"S5","article-title":"Type 2 diabetes: limitations of current therapies","volume":"49","author":"Philis-Tsimikas","year":"2009","journal-title":"Consultant"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2337\/diaclin.24.3.115","article-title":"Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management","volume":"24","author":"Briscoe","year":"2006","journal-title":"Clin Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1464-5491.2007.02341.x","article-title":"Hypoglycaemia in type 2 diabetes","volume":"25","author":"Amiel","year":"2008","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","article-title":"Hypoglycaemia in diabetes","volume":"26","author":"Cryer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/dmrr.865","article-title":"Vascular disease and diabetes: is hypoglycaemia an aggravating factor?","volume":"24","author":"Wright","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.smj.0000242864.17631.a2","article-title":"Management of diabetes-related hypoglycemia","volume":"100","author":"Boyle","year":"2007","journal-title":"South Med J"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3810\/pgm.2009.09.2056","article-title":"The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus","volume":"12","author":"Pi-Sunyer","year":"2009","journal-title":"Postgrad Med"},{"issue":"9 Suppl. C","key":"10.1111\/j.1742-1241.2010.02498.x-BIB9|cit9","first-page":"S2","article-title":"The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes","volume":"13","author":"Triplitt","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2010.02498.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","article-title":"Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes","volume":"34","author":"Gautier","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00125-005-0126-y","article-title":"Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans","volume":"49","author":"Meier","year":"2006","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB15|cit15","first-page":"4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycemia control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1152\/ajpendo.00373.2007","article-title":"Beneficial effect of GLP-1 on endothelial function in humans: dampening by glyburide but no glimepiride","volume":"293","author":"Basu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1677\/jme.0.0290347","article-title":"Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1","volume":"29","author":"Bulotta","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats","volume":"143","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/diacare.24.8.1416","article-title":"Glucagon-like peptide-1 infusion must be maintained for 24\u2003h\/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment","volume":"24","author":"Larsen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/ph3030764","article-title":"Liraglutide therapy for type 2 diabetes: overcoming unmet needs","volume":"3","author":"Sj\u00f6holm","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agers\u00f8","year":"2002","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02498.x-BIB25|cit25","first-page":"A164","article-title":"The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide","volume":"57","author":"Steensgaard","year":"2008","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycaemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB27|cit27","unstructured":"Novo Nordisk A\/S Liraglutide (Victoza \u00ae ) Summary of Product Characteristics [EMA Approval; Document on the Internet] http:\/\/emc.medicines.org.uk\/medicine\/21986\/SPC\/"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB28|cit28","unstructured":"Novo Nordisk A\/S Liraglutide (Victoza \u00ae ) Prescribing Information [Initial U.S. Approval; Document on the Internet] http:\/\/www.victozapro.com\/pdf\/Victoza_ComboPI_5.24.pdf"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB29|cit29","unstructured":"Novo Nordisk A\/S Novo Nordisk Receives Approval for Victoza \u00ae in Japan [Company Announcement; Document on the Internet] http:\/\/www.novonordisk.com\/include\/asp\/exe_news_attachment.pdf?sAttachmentGUID=e0808494-dc5e-4958-9a73-29758b30a9a2"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26\u2003weeks produces greater improvements in glycemia and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU)","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"Overview of 6\u2003years\u2019 therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study 16","volume":"44","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1995","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB38|cit38","first-page":"A593","article-title":"The once-daily human GLP-1 analogue liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline","volume":"57","author":"Russell-Jones","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies","volume":"373","author":"Prospective Study Collaboration","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.clinthera.2009.11.034","article-title":"A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus","volume":"31","author":"Montanya","year":"2009","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB44|cit44","unstructured":"American Association of Clinical Endocrinologists\/American College of Endocrinology AACE\/ACE Diabetes Algorithm for Glycemic Control, 2009 http:\/\/www.aace.com\/pub\/pdf\/GlycemicControlAlgorithmPPT.pdf"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB45|cit45","unstructured":"American Association of Clinical Endocrinologists Alert 2010 http:\/\/www.aace.com\/alert\/liraglutide03152010.php"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB47|cit47","first-page":"S26","article-title":"How to implement incretin therapy","volume":"57","author":"Cobble","year":"2008","journal-title":"J Fam Pract"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB48|cit48","unstructured":"Novo Nordisk A\/S Liraglutide (Victoza \u00ae ) Package Leaflet [EMA Approval; Document on the Internet] http:\/\/www.novonordisk.co.uk\/Images\/2009\/victoza-pil.pdf"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2006.10.004","article-title":"Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data","volume":"28","author":"Lee","year":"2006","journal-title":"Clin Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02498.x-BIB50|cit50","first-page":"A130","article-title":"randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects","volume":"57","author":"Malm-Erjef\u00e4lt","year":"2008","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02498.x-BIB51|cit51","first-page":"A566","article-title":"A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug","volume":"57","author":"Jacobsen","year":"2008","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0091270006288215","article-title":"An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide","volume":"46","author":"Damholt","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB53|cit53","unstructured":"Bode B Falahati A Brett J Pratley R Comparison of the efficacy and tolerability of the once-daily human GLP-1 analogue, liraglutide, in elderly versus younger patients with type 2 diabetes: a meta-analysis"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB54|cit54","unstructured":"Shomali M Hale P Zdravkovic M et\u00a0al. Liraglutide, a once-daily human GLP-1 analog, improves glycemic control more than glimepiride in African American or black individuals with type 2 diabetes (LEAD-3)"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB55|cit55","unstructured":"Amylin Pharmaceuticals, Inc Exenatide (BYETTA \u00ae ) Prescribing Information, 2008 http:\/\/pi.lilly.com\/us\/byetta-pi.pdf"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB56|cit56","unstructured":"Amylin Pharmaceuticals, Inc Exenatide (BYETTA \u00ae ) Summary of Product Characteristics, 2010 http:\/\/www.medicines.org.uk\/emc\/medicine\/19257"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis observed in patients with type 2 diabetes","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid c-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ncpendmet1023","article-title":"Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls","volume":"5","author":"Costante","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide - The FDA\u2019s review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"10.1111\/j.1742-1241.2010.02498.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J Clin Endocrinol Metab"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2010.02498.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2010.02498.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:09:21Z","timestamp":1643350161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2010.02498.x"}},"subtitle":["Liraglutide in practice"],"short-title":[],"issued":{"date-parts":[[2010,9,23]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02498.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,23]]}}}